Entera Bio Ltd. (ENTX) Form 10-Q — Aug 7, 2026

$ENTXForm 10-QFiled Aug 7, 2026, 4:09 PM ET0001178913-26-003947Original filing

Entera Bio filed its Q2 2026 10-Q showing a net loss of $7.3 million for the quarter and $10.8 million for the first half, more than double the year-ago period, with no revenue as R&D spending rose to $5.5 million ahead of the planned EB613 Phase 3. The report confirms a transformative July 2026 private placement: 134,803,910 shares and pre-funded warrants sold at $2.04 for approximately $275.0 million gross, with participation from funds affiliated with BVF Partners. Management stated the raise eliminated substantial doubt about the company's ability to continue as a going concern, and combined with $18.4 million of June 30 cash it funds operations into 2030.

Key figures

Eps: -$0.22 H1 2026 basic and diluted (vs -$0.12); -$0.14 Q2 2026 (vs -$0.06)
Revenue: 0
Net Income: -$10.8 million H1 2026 net loss (vs -$5.2 million H1 2025); Q2 2026 net loss -$7.3 million
Cash Position: $18.4 million cash, equivalents and restricted cash as of June 30, 2026 (including $7.1 million designated for OPKO collaboration), before the July raise
Gross Proceeds: $275.0 million (July 2026 private placement, before fees); $10.0 million (April 2026 private placement)
Offering Price: $2.04 per ordinary share (July 2026 placement); $1.2775 per unit (April 2026 placement)
Shares Offered: 134,803,910 ordinary shares/pre-funded warrants (July 2026); 7,827,789 units (April 2026)
Shares Outstanding: 173141831
Rd Expense: $5.5 million H1 2026 (vs $2.6 million H1 2025); $3.2 million Q2 2026
Cash Runway: Sufficient to fund planned operations into 2030
Operating Loss: $8.1 million H1 2026 (vs $5.2 million H1 2025); $4.6 million Q2 2026
Ceo Option Grant: 200,000 options at $2.81 exercise price approved August 5, 2026
Phase3 Trial Size: approximately 750 postmenopausal women, initiation planned late 2026
Authorized Shares: 350,000,000 (shareholder approval July 14, 2026)
Bvf Board Nominees: 2
Accumulated Deficit: $136.2 million as of June 30, 2026
Going Concern Status: Substantial doubt resolved following July 2026 private placement
Net Cash Used In Operations: $6.6 million H1 2026 (vs $3.0 million H1 2025)
Potential Warrant Proceeds: $22.3 million if all remaining 2023 and 2026 warrants exercised
Total Raised Since Inception: $121.8 million through June 30, 2026
Pre Funded Warrants Liability: $9.6 million at June 30, 2026; $2.755 million fair-value loss recognized in H1 2026

Price after filing

1 day: +2.1%7 days: +2.1%30 days: +6.8%

Close on the filing date to close N calendar days later (from $2.81). Historical, not a forecast.

AI analysis

Red flags8 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.